SLE: four trials to watch in 2026
As Spring edges closer, rheumatology experts are preparing for The European Lupus Society’s 15th Annual European Lupus Meeting, which will…
Trials to Watch
-
-
Multiple sclerosis: three trials to watch
September and October 2025 have proven busy for multiple sclerosis (MS) professionals, as many gathered at three major conferences to…
-
Prostate cancer: Three drug trials to watch
Today (19 November) marks International Men’s Day with the theme for 2024 being Men's Health Champions, shining a light on…
-
Trials to watch: Four biologics concluding pivotal COPD trials
The chronic obstructive pulmonary disorder (COPD) market has laid relatively dormant for the past few years until recently. Several biologics…
-
Trials to watch: Phase III BCG naïve non-muscle invasive bladder cancer
In 1980, scientists discovered something rather unexpected – the tuberculosis vaccine, Bacillus Calmette-Guérin (BCG) was effective in reducing the recurrence…
-
Trials to watch: Four ALS drugs to keep an eye on
It has been a turbulent few weeks for patients with amyotrophic lateral sclerosis (ALS) after Amylyx Pharmaceuticals pulled its lead…
-
Ovarian cancer: four drug trials to watch
Most patients with ovarian cancer are diagnosed at late stage as symptoms at early stages are minimal making it difficult…
-
Trials to watch: CRISPR pipeline accelerates after milestone Casgevy approval
December 2023 marked an important milestone in the life of clustered regularly interspaced short palindromic repeat (CRISPR) therapies after Vertex…
-
HIV: Three trials to watch in 2024
The year 2023 started with disappointing news for the field of human immunodeficiency virus (HIV) research after Janssen’s Phase III…
-
Trials to watch: Pipeline Parkinson’s drugs could revolutionise treatment
Last month, a new biomarker for Parkinson’s disease was discovered which showed that it develops even earlier than anticipated. Currently,…
